Medical oncologists' views on communicating with patients about chemotherapy costs: A pilot survey

Journal of Clinical Oncology

Volumn 25, Issue 2, 2007, Pages 233-237

  Schrag, Deborah ^a   Hanger, Morgan ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEHAVIOR; CANCER CHEMOTHERAPY; DECISION MAKING; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH SURVEY; HUMAN; MEDICAL PRACTICE; MEDICAL STAFF; ONCOLOGY; PHYSICIAN; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; RANDOM SAMPLE; REVIEW; TREATMENT PLANNING; UNITED STATES; VIGNETTE; WELLBEING; DOCTOR PATIENT RELATION; DRUG COST; ECONOMICS; HEALTH PERSONNEL ATTITUDE; INTERPERSONAL COMMUNICATION; NEOPLASM; PILOT STUDY; PSYCHOLOGICAL ASPECT;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; COMMUNICATION; DRUG COSTS; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; PHYSICIAN-PATIENT RELATIONS; PILOT PROJECTS;

EID: 33846994727     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.2437     Document Type: Review

References (18)

1. Schrag D: The price tag on progress: Chemotherapy for colorectal cancer. N Engl J Med 351:317-319, 2004
2. Huskamp HA, Deverka PA, Epstein AM, et al: The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 349:2224-2232, 2003
3. Shrank WH, Fox SA, Kirk A, et al: The effect of pharmacy benefit design on patient-physician communication about costs. J Gen Intern Med 21:334-339, 2006
4. Shrank WH, Joseph GJ, Choudhry NK, et al: Physicians' perceptions of relevant prescription drug costs: Do costs to the individual patient or to the population matter most? Am J Manag Care 12:545-551, 2006
5. Emanuel EJ: Cost savings at the end of life: What do the data show? JAMA 275:1907-1914, 1996
6. Alexander GC, Casalino LP, Tseng CW, et al: Barriers to patient-physician communication about out-of-pocket costs. J Gen Int Med 19:856-860, 2004
7. Alexander GC, Casalino LP, Meltzer DO: Patient-physician communication about out-of-pocket costs. JAMA 290:953-957, 2004
8. Nadler E, Eckert B, Neumann PJ: Do oncologists believe new cancer drugs offer good value? Oncologist 11:90-95, 2006
9. Jacobson M, O'Malley AJ, Earle CC, et al: Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff 25:437-443, 2006
10. Smith TJ, Bodurtha JN: Ethical considerations in oncology: Balancing the interests of patients, oncologists, and society. J Clin Oncol 13:2464-2470, 1995
11. Emanuel EJ, Dubler NN: Preserving the physician-patient relationship in the era of managed care. N Engl J Med 329:879-882, 1993
12. Weinstein MC: Should physicians be gatekeepers of medical resources? JAMA 273:323-329, 1995
13. Kahneman D, Tversky A: Prospect theory: An analysis of decision under risk. Econometrica XVLII: 263-291, 1979
14. Pearson SD: Caring and cost: The challenge for physician advocacy. J Med Ethics 27:268-274, 2001
15. Joffe S, Weeks JC: Views of American oncologists about the purposes of clinical trials. J Natl Cancer Inst 94:1847-1853, 2002
16. Chisholm MA, DiPiro JT: Pharmaceutical manufacturer assistance programs. Arch Intern Med 162:780-784, 2002
17. American Board of Internal Medicine Professionalism Project: Medical professionalism in the new millennium: Putting the charter into practice. Ann Intern Med 136: 243-246, 2002
18. Hardee JT, Platt FW, Kasper IK: Discussing health care costs with patients. Journal of General Internal Medicine 20:666-669, 2005